Corvus Pharmaceuticals Inc. (CRVS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $10.03 (-1.95% 1D, market cap $860.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVS ranks #920 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $856.7M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, CRVS leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).
Per CRVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626971), Corvus Pharmaceuticals Inc. generated $0 in revenue, -$15.3M in net income, and -$33.0M in free cash flow against $71.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CRVS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.86) and Max Pain ($10.53) forces dealer call-delta covering toward $28.30.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Corvus Pharmaceuticals Inc. (CRVS) slipped -1.95% to $10.03, trading at 18% of its 52-week range ($6.39 – $26.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Stocktwits report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRVS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRVS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Corvus Pharmaceuticals Inc. (CRVS) ranks #920 by composite RQD confidence (27/100, grade E) and #380 by equity capitalization ($860.6M). Within this direct 5-issuer industry benchmark cohort, CRVS leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PHAR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CRVS at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRVS
ACTIVE
Corvus Pharmaceuticals Inc. | E | 27/100 | — | — | -35.0% | -1.95% | $860.6M | Benchmark Subject |
| PHAR Pharming Group N.V. ADS each representing 10 | D | 51/100 | — | — | — | +0.82% | $856.7M | /phar-vs-crvs → |
| IVA Inventiva S.A. American Depository Shares | D | 49/100 | — | — | — | -2.14% | $881.3M | /iva-vs-crvs → |
| ALMS Alumis Inc. | E | 19/100 | — | — | -35.0% | -2.32% | $891.8M | /alms-vs-crvs → |
| OBX Obsidian Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +1.86% | $896.9M | /obx-vs-crvs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corvus Pharmaceuticals Inc. (CRVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.3M, operating cash flow of -$32.8M, and free cash flow of -$33.0M (-29.7% YoY). On the balance sheet, CRVS closed FY2025 with $71.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$15.3M | -$32.8M | -$33.0M | $71.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$62.3M | -$25.4M | -$25.4M | $68.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$27.0M | -$23.9M | -$23.9M | — | — |
As of 2026-11-02, Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $10.03 (-1.95% 1D, market cap $860.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVS ranks #920 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $856.7M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, CRVS leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).
Per CRVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626971), Corvus Pharmaceuticals Inc. generated $0 in revenue, -$15.3M in net income, and -$33.0M in free cash flow against $71.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRVS last traded at $10.03 (-1.95% on volume of 845,206 shares), positioning the stock -15.43% below its 50-day simple moving average ($11.86) and -30.64% below its 200-day simple moving average ($14.46). Across its 52-week range of $6.39 to $26.95, CRVS sits at the 17.7% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($8.84 to $11.22).
Why CRVS Stock slipped -1.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD rating assigns CRVS a score of 27 out of 100 and a letter grade of E, with a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:
Taken together, the score implies that the upside case rests on events outside the reported cash engine, such as the catalysts listed below, rather than on current fundamentals. A prospective investor would need to weigh the tradeoff between a stock price that has recovered sharply from its 52-week low and a set of pillars that are uniformly weak.
Corvus Pharmaceuticals Inc. (CRVS) is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry (per the profile). The company's products, customers, and revenue model are not described in the source data. Reported revenue is $0.0M in each of the periods provided (per the SEC financials), which indicates no reported revenue in those years.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-43.0M | $-15.3M | N/A | $-33.0M | $4.6M | N/A |
| FY 2024 | $0.0M | $-27.5M | $-62.3M | N/A | $-25.4M | $8.7M | N/A |
| FY 2023 | $0.0M | $-23.4M | $-27.0M | N/A | $-23.9M | N/A | N/A |
Per the SEC financials and market data, the company reports zero revenue and negative operating income, with operating, gross, and net margins all at 0% in the market data. ROIC is -35% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. The reported cash balance declined from $8.7M in FY 2024 to $4.6M in FY 2025 (per the SEC financials).
Risk watch: the market data shows the stock down -2.76% on the day, and the 52-week range is wide ($6.39 to $26.95). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no signal-level catalysts are confirmed beyond the news wire.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations, but no linkage to peers or suppliers is provided. An investor should treat the absence of mapped links as a gap in the available evidence rather than as evidence of independence.
Real-time company headlines, analyst actions, and sector developments for Corvus Pharmaceuticals Inc. (CRVS) • Click "Debate This Headline" to argue it in the Roar Pit below
Stocktwits report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Corvus Pharmaceuticals Inc. (CRVS) market action, institutional positioning, and fundamental catalysts.
Welcome to the CRVS (Corvus Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CRVS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Corvus Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CRVS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.23 (52-wk range $6.39 - $26.95), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).